SCHEMBL8968762

SCHEMBL8968762

CC(C)c1cccc(C(C)(C)N)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.50
PTPN5 P54829 2/20 0.41
HDAC4 P56524 2/20 0.41
HDAC8 Q9BY41 2/20 0.41
ALDH1A1 P00352 2/20 0.41
ALOX12 P18054 2/20 0.41
HTT P42858 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MDM4 O15151 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
TYR P14679 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
CA5A P35218 1/20 0.41
MDM2 Q00987 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31164894 0.86 PNMT (0.43) KIF11PNMTIDO1TDO2HTR2A
SCHEMBL15597549 0.86 HTR2A (0.41) KIF11PNMTIDO1TDO2HTR2A
SCHEMBL598661 0.83 KIF11 (0.49) KIF11PTPN5HDAC4HDAC8ALDH1A1
SCHEMBL4981920 0.83 KIF11 (0.49) KIF11PTPN5HDAC4HDAC8ALDH1A1
SCHEMBL16191335 0.83 KIF11 (0.49) KIF11PTPN5HDAC4HDAC8ALDH1A1
SCHEMBL255035 0.81 PNMT (0.55) KIF11PTPN5MAPTPNMTIDO1
SCHEMBL15597411 0.80 PNMT (0.39) KIF11HDAC4HTTSMN1; SMN2PNMT
SCHEMBL5252610 0.80 HTR2A (0.37) KIF11ALDH1A1KDM4EPNMTIDO1
SCHEMBL2138732 0.79 ESR1 (0.44) KIF11HDAC4HDAC8ALDH1A1MAPT
SCHEMBL24270379 0.79 KIF11 (0.46) KIF11PTPN5HDAC4HDAC8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4559918-A2 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2025-05-28 EP disclosed
EP-3673906-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2025-05-14 EP disclosed
CN-107080747-B Glucosylceramide synthase inhibitors 建新公司 2021-02-26 CN disclosed
EP-3673906-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2020-07-01 EP disclosed
US-20200048266-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2020-02-13 US disclosed
CN-107080747-A Glucosylceramide synthase inhibitor 建新公司 2017-08-22 CN disclosed
CN-103917094-B Glucosylceramide Synthase Inhibitors 建新公司 2016-11-09 CN disclosed
US-20160207933-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION 2016-07-21 US disclosed
US-9139580-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2015-09-22 US disclosed
US-9126993-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2015-09-08 US disclosed
US-20140371460-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION 2014-12-18 US disclosed
US-20140255381-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2014-09-11 US disclosed
CN-103917094-A Glucosylceramide synthase inhibitors GENZYME CORP 2014-07-09 CN disclosed
US-7312209-B2 Acridone inhibitors of IMPDH enzyme BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-25 US disclosed
EP-0600507-B1 3-Azabicyclo(3.1.0.)hexane-2-one derivatives and Herbicidal Compositions Containing them as Herbicidally Active Ingredients MITSUI TOATSU CHEMICALS (JP) 1996-03-06 EP disclosed
US-5352655-A Pre- and postemergence; rice MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1994-10-04 US disclosed
EP-0600507-A1 3-Azabicyclo(3.1.0.)hexane-2-one derivatives and Herbicidal Compositions Containing them as Herbicidally Active Ingredients MITSUI TOATSU CHEMICALS, Inc. (JP) 1994-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048266-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA KIF11 4441/4885PTPN5 4198/4885HDAC4 707/4885
US-20160207933-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA KIF11 4481/4885PTPN5 4219/4885HDAC4 684/4885
US-20140371460-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA KIF11 4481/4885PTPN5 4219/4885HDAC4 684/4885
US-20140255381-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA KIF11 4481/4885PTPN5 4219/4885HDAC4 684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.